// App-Quantinova.ai

4520 : Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.

Researchers

Presenter

  • Thomas Powles

Principal Investigators

  • Daniel P. Petrylak

  • Se Hoon Park

  • Srikala S. Sridhar

  • Claudia Caserta

  • Antoine Thiery Vuillemin

  • Hyo Jin Lee

  • Joaquim Bellmunt

  • Yoshiaki Yamamoto

  • Jeanny B. Aragon-Ching

  • Bo Huang

  • Keith A. Ching

  • Craig B. Davis

  • Alessandra Di Pietro

  • Yohann Loriot

  • Petros Grivas

Medical Centers

  • Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomews Hospital, London, United Kingdom

  • Yale Cancer Center, New Haven, CT

  • Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Canada.

  • Medical Oncology, Azienda Ospedaliera S. Maria, Terni, Italy

  • University Hospital of Besançon, Biochemistry, Besancon, France

  • Department of Medical Science, Chungnam National University School of Medicine, Daejeon, Republic of Korea

  • Department of Surgery, Division of Surgical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

  • Yamaguchi University, Ube, Japan

  • Inova Schar Cancer Institute, Fairfax, VA

  • Pfizer, Groton, CT

  • Pfizer Inc, New York, NY

  • Pfizer Oncology, La Jolla, CA

  • Pfizer Inc, Milan, Italy

  • Gustave Roussy, Universite Paris-Saclay, Villejuif, France

  • University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA

Locations

  • United Kingdom

  • United States

  • Canada

  • Italy

  • France

  • Japan

  • Republic of South Korea

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

  • Solute Carrier Family 12 Member 2

Drug/Treatment

  • Carboplatin

  • Gemcitabine

  • Cisplatin

  • Avelumab

  • SP263

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02603432

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved